News Agency
Men's Weekly

TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

  • Written by PR Newswire
TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain
  • The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) 
  • Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain reduction and favorable safety profiles among...

Read more: TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate...

Gender-Inclusive Lash Treatments: Breaking Beauty Norms

Beauty is no longer defined by traditional gender standards, and the lash industry is evolving to reflect that.  In 2026, more clients of all genders are seeking lash lifts, tints, and extensions that enhance their natural features while respecting individual style... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion